Contribution of reactive oxygen species to ovarian cancer cell growth arrest and killing by the anti-malarial drug artesunate

Molecular Carcinogenesis

Volumn 56, Issue 1, 2017, Pages 75-93

  Greenshields, Anna L ^a   Shepherd, Trevor G ^b   Hoskin, David W ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

artesunate; cell cycle arrest; cytotoxicity; ovarian cancer; reactive oxygen species

Indexed keywords

ARTESUNATE; CASPASE INHIBITOR; CYCLIN D3; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN P21; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR E2F1; ANTIMALARIAL AGENT; ANTINEOPLASTIC AGENT; ARTEMISININ DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER GROWTH; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL DEATH; CELL GROWTH; CELL KILLING; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; OVARIAN CANCER CELL LINE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANIMAL; APOPTOSIS; C57BL MOUSE; CELL CYCLE CHECKPOINT; CELL CYCLE G2 PHASE; DRUG EFFECTS; METABOLISM; OVARIAN NEOPLASMS; OVARY; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTIMALARIALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; ARTEMISININS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; G2 PHASE; HUMANS; MICE, INBRED C57BL; OVARIAN NEOPLASMS; OVARY; REACTIVE OXYGEN SPECIES;

EID: 84959194657     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.22474     Document Type: Article

References (62)

1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2015. CA Cancer J Clin 2015; 65:5–29.
2. Tavassoli FA. In: Devilee P, editor. World health organisation classification of tumors. Pathology and genetics of cancer. Tumors of the breast and female genital organs. Llyon: IARC Press; 2003.
3. Hennessy BT, Coleman RL, Markman M. Ovarian cancer. Lancet 2009; 374:1371–1382.
4. Romero I, Bast RC. Minireview: Human ovarian cancer: Biology, current management, and paths to personalizing therapy. Endocrinology 2012; 153:1593–1602.
5. Eckstein N. Platinum resistance in breast and ovarian cancer cell lines. J Exp Clin Cancer Res 2011; 30:91.
6. Li Y, Wu Y. An over four millennium story behind qinghaosu (artemisinin)—A fantastic antimalarial drug from a traditional Chinese herb. Curr Med Chem 2003; 10:2197–2230.
7. WHO. Guidlines for the treatment of malaria: Second edition. 2nd ed. Geneva: 2010.
8. O'Neill PM, Barton VE, Ward SA. The molecular mechanism of action of artemisinin—The debate continues. Molecules 2010; 15:1705–1721.
9. Efferth T. Willmar Schwabe Award 2006: Antiplasmodial and antitumor activity of artemisinin—From bench to bedside. Planta Med 2007; 73:299–309.
10. Shandilya A, Chacko S, Jayaram B, Ghosh I. A plausible mechanism for the antimalarial activity of artemisinin: A computational approach. Sci Rep 2013; 3:2513.
11. Ho WE, Peh HY, Chan TK, Wong WSF. Artemisinins: Pharmacological actions beyond anti-malarial. Pharmacol Ther 2014; 142:126–139.
12. Mercer AE, Maggs JL, Sun X-M, et al. Evidence for the involvement of carbon-centered radicals in the induction of apoptotic cell death by artemisinin compounds. J Biol Chem 2007; 282:9372–9382.
13. Du JH, Zhang HD, Ma ZJ, Ji KM. Artesunate induces oncosis-like cell death in vitro and has antitumor activity against pancreatic cancer xenografts in vivo. Cancer Chemother Pharmacol 2010; 65:895–902.
14. Hamacher-Brady A, Stein HA, Turschner S. et al. Artesunate activates mitochondrial apoptosis in breast cancer cells via iron-catalyzed lysosomal reactive oxygen species production. J Biol Chem 2011; 286:6587–6601.
15. Efferth T, Giaisi M, Merling A, Krammer PH, Li-Weber M. Artesunate induces ROS-mediated apoptosis in doxorubicin-resistant T leukemia cells. PLoS ONE 2007; 2:e693.
16. Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact 2006; 160:1–40.
17. Ozben T. Oxidative stress and apoptosis: Impact on cancer therapy. J Pharm Sci 2007; 96:2181–2196.
18. Adjuik M, Babiker A, Garner P, Olliaro P, Taylor W, White N. Artesunate combinations for treatment of malaria: Meta-analysis. Lancet 2004; 363:9–17.
19. Jiang Z, Chai J, Chuang HH. et al. Artesunate induces G0/G1 cell cycle arrest and iron-mediated mitochondrial apoptosis in A431 human epidermoid carcinoma cells. Anticancer Drugs 2012; 23:606–613.
20. Holien T, Olsen OE, Misund K. et al. Lymphoma and myeloma cells are highly sensitive to growth arrest and apoptosis induced by artesunate. Eur J Haematol 2013; 91:339–346.
21. Mosmann T. Rapid colorometric assay for cellular growth and survival: Application to proliferation and cytotoxic assays. J Immunol Meth 1983; 65:55–63.
22. Shepherd TG, Thériault BL, Campbell EJ, Nachtigal MW. Primary culture of ovarian surface epithelial cells and ascites-derived ovarian cancer cells from patients. Nat Protoc 2006; 1:2643–2649.
23. Vermeulen K, Van Bockstaele DR, Berneman ZN. The cell cycle: A review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif 2003; 36:131–149.
24. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell 2013; 149:274–293.
25. Dixon SJ, Lemberg KM, Lamprecht MR. et al. Ferroptosis: An iron-dependent form of nonapoptotic cell death. Cell 2012; 149:1060–1072.
26. Vanlangenakker N, Vanden Berghe T, Vandenabeele P. Many stimuli pull the necrotic trigger, an overview. Cell Death Differ 2012; 19:75–86.
27. Chen T, Chen M, Chen J. Ionizing radiation potentiates dihydroartemisinin-induced apoptosis of A549 cells via a caspase-8-dependent pathway. PLoS ONE 2013; 8:e59827.
28. Hou J, Wang D, Zhang R, Wang H. Experimental therapy of hepatoma with artemisinin and its derivatives: In vitro and in vivo activity, chemosensitization, and mechanisms of action. Clin Cancer Res 2008; 14:5519–5530.
29. Sun H, Meng X, Han J. et al. Anti-cancer activity of DHA on gastric cancer-an in vitro and in vivo study. Tumour Biol 2013; 34:3791–3800.
30. Jiao Y, Ge CM, Meng QH, Cao JP, Tong J, Fan SJ. Dihydroartemisinin is an inhibitor of ovarian cancer cell growth. Acta Pharmacol Sin 2007; 28:1045–1056.
31. Chen T, Li M, Zhang R, Wang H. Dihydroartemisinin induces apoptosis and sensitizes human ovarian cancer cells to carboplatin therapy. J Cell Mol Med 2009; 13:1358–1370.
32. Efferth T, Dunstan H, Sauerbrey A, Miyachi H, Chitambar CR. The anti-malarial artesunate is also active against cancer. Int J Oncol 2001; 18:767–773.
33. Orth K, Hung J, Gazdar A, Bowcock A, Mathis JM, Sambrook J. Genetic instability in human ovarian cancer cell lines. Proc Natl Acad Sci USA 1994; 91:9495–9499.
34. Shield K, Ackland ML, Ahmed N, Rice GE. Multicellular spheroids in ovarian cancer metastases: Biology and pathology. Gynecol Oncol 2009; 113:143–148.
35. Gautam A, Ahmed T, Batra V, Paliwal J. Pharmacokinetics and pharmacodynamics of endoperoxide antimalarials. Curr Drug Metab 2009; 10:289–306.
36. Mercer AE, Copple IM, Maggs JL, O'Neill PM, Park BK. The role of heme and the mitochondrion in the chemical and molecular mechanisms of mammalian cell death induced by the artemisinin antimalarials. J Biol Chem 2011; 286:987–996.
37. Harbour JW, Luo RX, Dei Santi A, Postigo AA, Dean DC. Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell 1999; 98:859–869.
38. Bracken AP, Ciro M, Cocito A, Helin K. E2F target genes: Unraveling the biology. Trends Biochem Sci 2004; 29:409–417.
39. Altomare DA, Wang HQ, Skele KL. et al. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene 2004; 23:5853–5857.
40. Chen K, Shou L-M, Lin F. et al. Artesunate induces G2/M cell cycle arrest through autophagy induction in breast cancer cells. Anticancer Drugs 2014;1–11.
41. Du X-X, Li Y-J, Wu C-L. et al. Initiation of apoptosis, cell cycle arrest and autophagy of esophageal cancer cells by dihydroartemisinin. Biomed Pharmacother 2013; 67:417–424.
42. Huang X-J, Ma Z-Q, Zhang W-P, Lu Y-B, Wei E-Q. Dihydroartemisinin exerts cytotoxic effects and inhibits hypoxia inducible factor-1alpha activation in C6 glioma cells. J Pharm Pharmacol 2007; 59:849–856.
43. Zhao YG, Wang Y, Guo Z. et al. Dihydroartemisinin ameliorates inflammatory disease by its reciprocal effects on Th and regulatory T cell function via modulating the mammalian target of rapamycin pathway. J Immunol 2012; 189:4417–4425.
44. Odaka Y, Xu B, Luo Y. et al. Dihydroartemisinin inhibits the mammalian target of rapamycin-mediated signaling pathways in tumor cells. Carcinogenesis 2014; 35:192–200.
45. Berdelle N, Nikolova T, Quiros S, Efferth T, Kaina B. Artesunate induces oxidative DNA damage, sustained DNA double-strand breaks, and the ATM/ATR damage response in cancer cells. Mol Cancer Ther 2011; 10:2224–2233.
46. Torti SV, Torti FM. Iron and cancer: More ore to be mined. Nat Rev Cancer 2013; 13:342–355.
47. Zhou X, Sun W, Wang W. et al. Artesunate inhibits the growth of gastric cancer cells through the mechanism of promoting oncosis both in vitro and in vivo. Anticancer Drugs 2013; 24:920–927.
48. Yu X, Deng Q, Bode AM, Dong Z, Cao Y. The role of necroptosis, an alternative form of cell death, in cancer therapy. Expert Rev Anticancer Ther 2013; 13:883–893.
49. Button RW, Lin F, Ercolano E. et al. Artesunate induces necrotic cell death in schwannoma cells. Cell Death Dis 2014; 5:e1466.
50. Eling N, Reuter L, Hazin J, Hamacher-Brady A, Brady NR. Identification of artesunate as a specific activator of ferroptosis in pancreatic cancer cells. Oncoscience 2015; 2:517–532.
51. Friedmann Angeli JP, Schneider M, Proneth B, et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat Cell Biol 2014; 3:1–9.
52. Li PCH, Lam E, Roos WP, Zdzienicka MZMZ, Kaina B, Efferth T. Artesunate derived from traditional Chinese medicine induces DNA damage and repair. Cancer Res 2008; 68:4347–4351.
53. Wang B, Hou D, Liu Q, et al. Artesunate sensitizes ovarian cancer cells to cisplatin by downregulating RAD51. Cancer Biol Ther 2015; 4047:1–9.
54. Hanahan D, Weinberg R. Hallmarks of cancer: The next generation. Cell 2011; 144:646–674.
55. Provencher DM, Lounis H, Champoux L. et al. Characterization of four novel epithelial ovarian cancer cell lines. In Vitro Cell Dev Biol Anim 2000; 36:357–361.
56. Petitjean A, Mathe E, Kato S. et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: Lessons from recent developments in the IARC TP53 database. Hum Mutat 2007; 28:622–629.
57. Hamilton TC, Young RC, Mckoy WM. et al. Characterization of a human ovarian carcinoma cell line (NIH: OVCAR-3) with androgen and estrogen receptors. Cancer Res 1983; 43:5379–5389.
58. Shaw TJ, Senterman MK, Dawson K, Crane CA, Vanderhyden BC. Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer. Mol Ther 2004; 10:1032–1042.
59. Fogh J. Human tumor cells in vitro. New York: Plenum Press; 1975.
60. Domcke S, Sinha R, Levine DA, Sander C, Schultz N. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun 2013; 4:2126.
61. Buick RN, Pullano R, Trent JM. Comparative properties of five human ovarian adenocarcinoma cell lines. Cancer Res 1985; 45:3668–3676.
62. Bénard J, Silva Da J, Blois De M, et al. Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice. Cancer Res 1985; 45:4970–4979.